Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00958126 · ClinicalTrials.gov registry record · Phase 2
A Clinical Trial of CSL's 2009 H1N1 Influenza Vaccine (CSL425) in Healthy Adults in the USA
A Phase 2 study, sponsored by Seqirus.
- Completed
- Registry status
- Phase 2
- Development phase
- 1,313
- Enrollment target
NCT00958126 is a Phase 2 study that has completed, run by Seqirus. The registered enrollment target is 1,313 participants.
The verdict
NCT00958126, a Phase 2 study, has completed, sponsored by Seqirus.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 1,313 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether CSL425 is a safe and effective vaccine for eliciting an immune response to H1N1 influenza in healthy adults
Interventions
- BIOLOGICAL Placebo
- BIOLOGICAL CSL425
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,313 participants |
| Start Date | 2009-08 |
| Est. Completion | 2010-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00958126
The ClinicalTrials.gov registry entry for NCT00958126 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 1,313 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Seqirus, which has 25 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00958126 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00958126 about?
NCT00958126 is a clinical study titled "A Clinical Trial of CSL's 2009 H1N1 Influenza Vaccine (CSL425) in Healthy Adults in the USA". The purpose of this study is to determine whether CSL425 is a safe and effective vaccine for eliciting an immune response to H1N1 influenza in healthy adults
What is the current status of trial NCT00958126?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 1,313 participants. The study started on 2009-08. Estimated completion is 2010-04.
What interventions are being tested in trial NCT00958126?
The interventions under investigation include: Placebo (BIOLOGICAL), CSL425 (BIOLOGICAL).
Who is sponsoring clinical trial NCT00958126?
This trial is sponsored by Seqirus, which has 25 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.